- \n
- New evidence for established standard-of-care therapies, with updates for LORBRENA\u00ae<\/sup> in ALK-positive metastatic non<\/i>\u2011small cell lung cancer and a BRAFTOVI\u00ae<\/sup> regimen in a type of BRAF-mutant colorectal cancer<\/i><\/li>\n
- Extending potential impact of innovative therapies in earlier lines of treatment, including TALZENNA\u00ae<\/sup> plus XTANDI\u00ae<\/sup> in metastatic castration-sensitive prostate cancer and TUKYSA\u00ae<\/sup> as first-line maintenance for HER2-positive breast cancer<\/i><\/li>\n
- New and updated data from next-generation pipeline of novel mechanisms and differentiated combinations across solid tumors, including sigvotatug vedotin, PF-08634404 and atirmociclib<\/i><\/li>\n<\/ul>\n
NEW YORK–(BUSINESS WIRE<\/a>)–
\nPfizer Inc. (NYSE: PFE) will present new data across its diverse, industry-leading Oncology pipeline and portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 29 \u2013 June 2, 2026, in Chicago. Data from more than 40 company-sponsored, investigator-sponsored and collaborative research abstracts, including three late-breaking sessions and eight oral and rapid oral presentations, will be shared. These data highlight Pfizer\u2019s leadership in establishing potential new standards of care across multiple cancer types and its next-generation pipeline of novel targets and combination strategies designed to extend impact into broader patient populations and earlier lines of therapy.<\/p>\n\n\u201cFor people living with cancer and their families, every moment matters. We are moving with urgency to drive advances that have the potential to change standards of care \u2013 and striving to bring new, innovative options to patients in earlier lines of therapy,\u201d said Jeff Legos, Chief Oncology Officer, Pfizer. \u201cOur progress is evident in the data presented at ASCO this year, which span our portfolio of established therapies, as well as next-generation, early-stage clinical research from one of the industry\u2019s largest oncology R&D programs. Together, these results reinforce our ability to advance breakthroughs that may redefine clinical practice and change the lives of people with cancer.\u201d<\/p>\n
\nKey highlights of Pfizer\u2019s presence at ASCO include:<\/p>\n
Sharing new evidence for standard-of-care therapies in certain types of biomarker-driven colorectal and lung cancers<\/b><\/p>\n
- \n
- \nSeven-year update from the pivotal Phase 3 CROWN study further supports LORBRENA\u00ae<\/sup> (lorlatinib) as a guideline-recommended first-line treatment for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).<\/p>\n<\/li>\n
- \nLate-breaking presentation of progression-free survival (PFS) and overall survival (OS) data from Cohort 3 of the BREAKWATER* trial evaluating BRAFTOVI\u00ae<\/sup> (encorafenib) in combination with cetuximab and FOLFIRI (fluorouracil, leucovorin and irinotecan) as a first-line regimen for patients with BRAF V600E-<\/i>mutant metastatic colorectal cancer (mCRC). These pivotal data further establish the benefit of this BRAFTOVI regimen following the U.S. Food and Drug Administration (FDA) full approval<\/a> and the topline results announcement<\/a> for objective response rate (ORR) from this Cohort earlier this year.<\/p>\n<\/li>\n<\/ul>\n
Showcasing data on potential benefit of treatments in earlier lines of therapy for prostate and breast cancers<\/b><\/p>\n
- \n
- \nLate-breaking presentation from the Phase 3 TALAPRO-3 study will highlight clinically meaningful radiographic progression-free survival (rPFS) benefit for TALZENNA\u00ae<\/sup> (talazoparib) plus XTANDI\u00ae<\/sup>** (enzalutamide) in metastatic castration\u2011sensitive prostate cancer (mCSPC) patients with homologous recombination repair gene alterations, with effects consistent across subgroups and a strong OS trend. These data follow the announcement of topline results<\/a> in March 2026 and support the potential of TALZENNA plus XTANDI to deliver benefit earlier in the disease course.<\/p>\n<\/li>\n
- \nAdditional efficacy and safety outcomes by stratified subgroups from the Phase 3 HER2CLIMB-05 study investigating TUKYSA\u00ae<\/sup> (tucatinib) in combination with trastuzumab and pertuzumab as first-line maintenance therapy for human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). These results support TUKYSA\u2019s potential use as part of a chemotherapy-free, first-line maintenance strategy for HER2+ MBC.<\/p>\n<\/li>\n<\/ul>\n
Advancing next-generation pipeline of novel mechanisms and differentiated combinations across solid tumors<\/b><\/p>\n
- \n
- \nUpdated Phase 2 data for PF\u201108634404 (PF\u20194404), a novel bispecific antibody targeting PD-1 and VEGF, as monotherapy in first-line PD-L1-expressing NSCLC. PF\u20194404 is being developed as a potential backbone therapy across tumor types, including an ongoing Symbiotic-Lung-01 Phase 3 study in combination with chemotherapy in first-line NSCLC regardless of PD-L1 expression and an ongoing Symbiotic-GI-03 Phase 3 study in first-line mCRC.<\/p>\n<\/li>\n
- \nUpdated results from a Phase 1 study of sigvotatug vedotin (SV), a novel integrin \u03b26 (IB6)\u2013directed ADC, in combination with pembrolizumab in NSCLC. These data support the ongoing SigVie-003 Phase 3 study of SV in combination with pembrolizumab in first-line NSCLC. An additional ongoing Phase 3 study, SigVie-002, is evaluating SV monotherapy in patients previously treated for advanced NSCLC.<\/p>\n<\/li>\n
- \nThe first results from a Phase 2 study of neoadjuvant atirmociclib, a highly selective CDK4 inhibitor, in combination with letrozole versus letrozole alone in people with hormone receptor-positive (HR+), HER2- breast cancer. Atirmociclib is being developed as a potential first-in-class, next-generation cell cycle inhibitor backbone for HR+, HER2- breast cancer in the early adjuvant and first-line metastatic setting.<\/p>\n<\/li>\n
- \nFindings from a Phase 1b study of a brain-penetrant MEK inhibitor, PF-07799544 (polfurmetinib), plus a next-generation BRAF inhibitor, PF-07799933 (claturafenib), in advanced BRAF-mutant melanoma.<\/p>\n<\/li>\n<\/ul>\n
\nInformation on significant Pfizer and partner-sponsored abstracts, including date and time of presentation, follows in the chart below. A complete list of Pfizer and partner-sponsored abstracts and presentations is available here<\/a>.<\/p>\n
- \nAdditional efficacy and safety outcomes by stratified subgroups from the Phase 3 HER2CLIMB-05 study investigating TUKYSA\u00ae<\/sup> (tucatinib) in combination with trastuzumab and pertuzumab as first-line maintenance therapy for human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC). These results support TUKYSA\u2019s potential use as part of a chemotherapy-free, first-line maintenance strategy for HER2+ MBC.<\/p>\n<\/li>\n<\/ul>\n
- \nLate-breaking presentation of progression-free survival (PFS) and overall survival (OS) data from Cohort 3 of the BREAKWATER* trial evaluating BRAFTOVI\u00ae<\/sup> (encorafenib) in combination with cetuximab and FOLFIRI (fluorouracil, leucovorin and irinotecan) as a first-line regimen for patients with BRAF V600E-<\/i>mutant metastatic colorectal cancer (mCRC). These pivotal data further establish the benefit of this BRAFTOVI regimen following the U.S. Food and Drug Administration (FDA) full approval<\/a> and the topline results announcement<\/a> for objective response rate (ORR) from this Cohort earlier this year.<\/p>\n<\/li>\n<\/ul>\n
- Extending potential impact of innovative therapies in earlier lines of treatment, including TALZENNA\u00ae<\/sup> plus XTANDI\u00ae<\/sup> in metastatic castration-sensitive prostate cancer and TUKYSA\u00ae<\/sup> as first-line maintenance for HER2-positive breast cancer<\/i><\/li>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20260420004885\/en\/1045874\/3\/Pfizer_Logo_Color_RGB_APPROVED.jpg\"){kind=logo}
<\/td>\n<\/tr>\n